Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

IMPORTANCE: Guidelines currently recommend ticagrelor over clopidogrel for patients with acute coronary syndrome (ACS) based on randomized clinical trial data in which ticagrelor reduced major adverse coronary events (MACE) vs clopidogrel but increased bleeding and dyspnea. OBJECTIVE: To compare the...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JAMA Intern Med
Auteurs principaux: Turgeon, Ricky D., Koshman, Sheri L., Youngson, Erik, Har, Bryan, Wilton, Stephen B., James, Matthew T., Graham, Michelle M.
Format: Artigo
Langue:Inglês
Publié: American Medical Association 2020
Sujets:
Original Investigation
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6990835/
https://ncbi.nlm.nih.gov/pubmed/31930361
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2019.6447
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires